Private equity firm Inflexion has sold medical data disseminator Pharmaspectra to US-listed health information company IQVIA, generating a 25% IRR.
The deal was valued at USD 100m, according to a source familiar with the situation.
The GP said it increased the company's client base by 160% over three years by investing in sales, marketing and client services. Inflexion added that it also supported market entry into China and the build-out of the team in India.
Inflexion has made nine exits to date in 2022 with a combined valuation of GBP 2.5bn, it said in a statement.
The GP closed its latest enterprise fund Fund V in May 2019 at GBP 400m.
Inflexion - Ben Long (partner), Saloshnee Nightingale (assistant director) and Andrea Johnson (investment executive).
Pharmaspectra - Jez Moulding (CEO).
Pharmaspectra hosts a continuously updated and integrated online repository of disseminated medical science information. This includes 16m meeting presentations, 28m publication abstracts, and 417,000 clinical trial results. This data is used across the pharmaceutical sector in which Pharmaspectra has an expansive and diverse customer base, including 13 of the top 20 pharma companies.
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater